期刊文献+

三阴性乳腺癌的临床病理特征及TopoⅡα、Ki67表达 被引量:2

Clinicopathological characteristics and expression of Topo Ⅱα, Ki67 in triple negative breast cancer
暂未订购
导出
摘要 目的 探讨三阴性乳腺癌的临床病理特征及TopoⅡα、Ki67表达情况.方法 分析78例三阴性乳腺癌患者发病年龄、肿瘤大小、组织学类型、淋巴结转移情况;同时采用免疫组化EnVision二步法检测TopoⅡα、Ki67蛋白表达水平,并与同期1 14例非三阴性乳腺癌患者比较.结果 三阴性乳腺癌组患者腋窝淋巴结转移率高于非三阴性乳腺癌患者,两组比较差异有统计学意义(P<0.05);随着肿瘤的增大,三阴性乳腺癌患者腋窝淋巴结转移率明显增高,两者呈正相关(P< 0.05);Non-TNBC组Ki67阳性率低于TNBC组,差异有统计学意义(x2=4.003,P=0.045).结论 三阴性乳腺癌侵袭性强、淋巴结转移率高,具有更高的肿瘤增殖活性,预后较其他类型患者差. Objective To investigate the clinicopathological characteristics and the expression of Topo Ⅱ α,Ki67 in triple negative breast cancer (TNBC).Methods The clinicopathological characteristics in TNBC group were analyzed,including year,tumor size,lymph node metastasis and histological type; the expression of Topo Ⅱ α and Ki67 was determined by immunohistochemical techniques (EnVision).And we compared the differences between TNBC group (78 cases) and the non-triple negative breast cancer (nonTNBC) group (114 cases).Results The positive rate of axillary lymph node metastasis in TNBC group was higher than that in non-TNBC group,which difference was significant (P < 0.05) ; With the increase of the tumor size,the positive rate of axillary lymph node metastasis in TNBC group was significantly higher,The positive rate of axillary lymph node metastasis was correlated positively with the tumor size (P < 0.05) ;the expression of Ki67 in non-TNBC group was significantly lower than that in TNBC group (x 2=4.003,P=0.045).Conclusion Compared with non-TNBC group patients,TNBC group patients have a higher risk of local invasion,lymph node metastasis,cell proliferation and poorer survival.
出处 《国际医药卫生导报》 2014年第3期325-328,共4页 International Medicine and Health Guidance News
关键词 乳腺肿瘤 三阴性 TopoⅡα KI67 Breast neoplasm Triple negative Topo Ⅱα Ki67
  • 相关文献

参考文献13

二级参考文献76

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量:126
  • 2何振宇,李彪,胡英,管迅行.Ki67在乳腺癌组织中的表达及临床病理分析[J].中国初级卫生保健,2005,19(12):94-95. 被引量:16
  • 3孙丽梅,王鲁建,宋敏,宋继谒.乳腺癌中耐药蛋白P-gp、GST-π、Topo-Ⅱ的表达[J].中国组织化学与细胞化学杂志,2006,15(2):169-172. 被引量:10
  • 4孙希印,周晓秋,高虹,李新功.P-gp、GST-π、TopoⅡ、p53在乳腺癌中的表达及相关性[J].中国现代普通外科进展,2007,10(3):224-226. 被引量:9
  • 5Perou C M,Sorlie T,Eisen M B,et al. Molecular portraits of human breast tumours[J]. Nature, 2000,706:747-752.
  • 6Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics[J]. CA Cancer J Clin, 2005,55(2):74-108.
  • 7Bauer K R,Brown M,Cress R D,et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor (PR)- negative,and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: A population-based study from the California Cancer Registry[J]. Cancer, 2007, 109: 1721-1728.
  • 8Dent R, Trudeau M, Pritehard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res , 2007,13:4429-4434.
  • 9Haffty B G, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [J]. J Clin Oncol, 2006, 24: 5652-5657.
  • 10Rakha E A, El-Sayed M E,Green A R,et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109: 25-32.

共引文献98

同被引文献19

  • 1Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J].N Engl J Med, 2010, 363(20):1938-1948. DOI: lO.1056/NEJMra1001389.
  • 2Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges[J].Pharmacol Ther, 2014, 141(2):140-149.
  • 3Cui H, Kong Y, Xu M, et al. Notch3 functions as a tumor suppressor by controlling cellular senescence[J].Cancer Res, 2013, 73(11):3451-3459. DOI: 10.1158/0008-5472.CAN-12-3902.
  • 4Chen CF, Dou XW, Liang YK, et al.Notch3 overexpression causes arrest of cell cycle progression by inducing Cdhl expression in human breast cancer cells[J].Cell Cycle, 2016, 15(3):432-440. DOI: 10.1080/15384101.2015.1127474.
  • 5Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF- kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice[J]. EMBO J, 2000, 19(13):3337-3348.
  • 6Bellavia D, Campese AF, Checquolo S, et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis[J].Proc Natt Acad Sci U S A, 2002, 99(6):3788-3793.
  • 7Gramantieri L, Giovannini C, Lanzi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular earcinoma[J].Liver Int, 2007, 27(7):997-1007.
  • 8Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes[J].Gynecol Oncol, 2010, 117(3):409-416. DOI: 10.1016/j.ygyno.2010.03.004.
  • 9Park JT, Chen X, Trop 6 CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to earboplatin[J].Am J Pathol, 2010, 177(3):1087-1094. DOI: lO.2353/ajpath.2010.100316.
  • 10Hu C, Di 6 vart A, Lupien M, et al. Overexpression of activated murine Notehl and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors[J].Am J Pathol, 2006, 168(3):973-990.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部